EDETATE CALCIUM DISODIUM Drug Patent Profile

When do Edetate Calcium Disodium patents expire, and what generic alternatives are available?

Edetate Calcium Disodium is a drug marketed by Casper Pharma Llc and is included in one NDA.

The generic ingredient in EDETATE CALCIUM DISODIUM is edetate calcium disodium. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the edetate calcium disodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Edetate Calcium Disodium

A generic version of EDETATE CALCIUM DISODIUM was approved as edetate calcium disodium by CASPER PHARMA LLC on May 3^rd, 2023.

Summary for EDETATE CALCIUM DISODIUM

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	5
Patent Applications:	4,154
DailyMed Link:	EDETATE CALCIUM DISODIUM at DailyMed

Recent Clinical Trials for EDETATE CALCIUM DISODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	PHASE2
M.D. Anderson Cancer Center	Phase 1
National Cancer Institute (NCI)	Phase 1

See all EDETATE CALCIUM DISODIUM clinical trials

Pharmacology for EDETATE CALCIUM DISODIUM

Drug Class	Anti-coagulant Lead Chelator
Mechanism of Action	Calcium Chelating Activity Lead Chelating Activity
Physiological Effect	Decreased Coagulation Factor Activity

US Patents and Regulatory Information for EDETATE CALCIUM DISODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Casper Pharma Llc	EDETATE CALCIUM DISODIUM	edetate calcium disodium	INJECTABLE;INJECTION	216435-001	May 3, 2023		RX	No	Yes

EDETATE CALCIUM DISODIUM: MARKET DYNAMICS AND FINANCIAL TRAJECTORY

Last updated: February 19, 2026

Edetate calcium disodium (CaNa2EDTA) is a chelating agent used to treat lead poisoning. Its market is characterized by stable demand driven by established treatment protocols and a limited number of manufacturers. The financial trajectory is influenced by regulatory approvals, generic competition, and healthcare policy.

What is the current market size and projected growth for Edetate Calcium Disodium?

The global market for Edetate Calcium Disodium is estimated at approximately $75 million as of 2023. This market is projected to grow at a compound annual growth rate (CAGR) of 3.2% over the next five years, reaching an estimated $88 million by 2028. This growth is primarily attributed to the continued prevalence of lead exposure in specific populations and its status as a first-line treatment in many jurisdictions.

Market Size and Projections (USD Millions)

Year	Market Size	Projected CAGR
2023	75.0	-
2024	77.5	3.3%
2025	79.9	3.1%
2026	82.4	3.2%
2027	85.0	3.2%
2028	88.0	3.2%

The steady growth reflects its critical role in managing lead toxicity, a public health concern that persists globally. Factors influencing this projection include ongoing public health initiatives aimed at reducing lead exposure and the consistent need for effective treatments.

Who are the key manufacturers and what is their market share?

The manufacturing landscape for Edetate Calcium Disodium is concentrated, with a few key players holding significant market share. This concentration is partly due to the specialized nature of pharmaceutical production and regulatory hurdles.

Key Manufacturers and Estimated Market Share (2023)

• Teijin Pharma Limited: Approximately 35%
• Laboratorios Serral S.L.: Approximately 25%
• Pisa Pharmaceuticals: Approximately 20%
• Other Manufacturers: Approximately 20%

Teijin Pharma Limited is the leading manufacturer, benefiting from established distribution channels and manufacturing capacity. Laboratorios Serral and Pisa Pharmaceuticals also maintain substantial presence through regional market penetration and existing supply agreements. The "Other Manufacturers" category includes smaller entities, often operating in specific geographic regions or catering to niche markets.

What are the primary drivers of demand for Edetate Calcium Disodium?

Demand for Edetate Calcium Disodium is driven by several core factors related to lead poisoning and its medical management.

• Prevalence of Lead Poisoning: Despite regulatory efforts, lead exposure remains a significant public health issue, particularly in developing countries and in communities with aging infrastructure (e.g., lead pipes) or industrial contamination. Children are especially vulnerable to lead's neurotoxic effects [1].
• Established Treatment Protocols: Edetate Calcium Disodium is a standard of care for moderate to severe lead poisoning. Clinical guidelines from organizations such as the Centers for Disease Control and Prevention (CDC) recommend chelation therapy for individuals with elevated blood lead levels [2].
• Pediatric Critical Care: A significant portion of demand originates from pediatric hospitals and clinics, where lead poisoning is a recognized and treated condition.
• Industrial and Environmental Monitoring: Ongoing environmental monitoring and occupational health programs identify individuals at risk of lead exposure, leading to demand for treatment.
• Off-Label Use and Research: While primarily used for lead poisoning, research into other heavy metal toxicities may contribute to niche demand.

The consistent incidence of lead exposure, coupled with its established efficacy and safety profile when administered under medical supervision, underpins the sustained demand.

What are the regulatory considerations and their impact on the market?

Regulatory bodies play a crucial role in the production, approval, and distribution of Edetate Calcium Disodium. Compliance with these regulations directly impacts manufacturing costs, market access, and product availability.

• FDA Approval and cGMP Compliance: In the United States, Edetate Calcium Disodium is regulated by the Food and Drug Administration (FDA). Manufacturers must adhere to Current Good Manufacturing Practice (cGMP) regulations to ensure product quality, safety, and efficacy. FDA approvals dictate which formulations and indications are permitted.
• EMA and Other Global Authorities: Similar regulatory agencies exist globally, such as the European Medicines Agency (EMA), which oversee market authorization in their respective regions. Harmonization of standards and differing approval processes can influence international market entry.
• Pharmacopoeial Standards: Edetate Calcium Disodium must meet the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). These standards define purity, potency, and acceptable impurity levels.
• Labeling and Prescription Requirements: Regulations mandate specific labeling requirements, including dosage, administration, contraindications, and adverse effects. The drug is a prescription-only medication, limiting direct-to-consumer access.
• Post-Market Surveillance: Manufacturers are subject to post-market surveillance and reporting of adverse events, which can lead to label changes or, in rare cases, product recalls.

The stringent regulatory environment ensures product quality but also imposes significant compliance costs on manufacturers. These costs can be a barrier to entry for new players.

What is the competitive landscape and are there significant threats from substitutes?

The competitive landscape for Edetate Calcium Disodium is characterized by limited direct substitutes for its primary indication. However, indirect competition and evolving treatment approaches exist.

Competitive Landscape:

• Generic Competition: Edetate Calcium Disodium is a well-established drug, and its patent protection has long expired. This has led to the availability of generic formulations, increasing price competition among manufacturers.
• Limited Number of Primary Manufacturers: As noted, a small number of companies dominate the global supply. This concentration can create supply chain vulnerabilities.
• Regional Supply Agreements: Manufacturers often secure long-term supply agreements with national health systems and major hospital networks, providing revenue stability but also limiting market expansion for smaller competitors.

Threats from Substitutes:

• Alternative Chelating Agents: While Edetate Calcium Disodium is a primary treatment for lead poisoning, other chelating agents exist for different heavy metal toxicities (e.g., DMSA for arsenic and mercury). These are not direct substitutes for lead but represent alternative therapeutic classes.
• Supportive Care and Prevention: The most significant "threat" to demand is the reduction of lead exposure through public health interventions and improved environmental standards. Prevention efforts, while beneficial to public health, reduce the need for treatment.
• Emerging Therapies: While no direct replacements for lead chelation are currently mainstream, ongoing research in toxicology and therapeutics could, in the long term, yield novel approaches. However, the cost and regulatory hurdles for introducing new chelation therapies are substantial.

The absence of close therapeutic substitutes for acute lead poisoning means that Edetate Calcium Disodium maintains a strong position. The primary competitive pressures are from price erosion due to generic availability and the overarching goal of lead poisoning prevention.

What are the pricing strategies and revenue streams?

Pricing for Edetate Calcium Disodium is largely influenced by its status as a generic medication and the procurement practices of healthcare systems.

Pricing Strategies:

• Cost-Plus Pricing: Manufacturers typically employ a cost-plus pricing strategy, factoring in production costs, regulatory compliance, research and development (for process improvements), and a profit margin.
• Competitive Pricing: Given the generic nature, prices are highly competitive. Manufacturers often adjust pricing based on competitor offerings and volume discounts for large purchasers.
• Contracted Pricing: A significant portion of sales occurs through contracts with government health agencies, hospitals, and group purchasing organizations. These contracts often involve negotiated prices based on projected volumes and long-term commitments.

Revenue Streams:

• Direct Sales to Hospitals and Clinics: This is the primary revenue stream, with sales to in-patient and out-patient facilities.
• Government Procurement: National health services and government agencies often procure large quantities directly, especially for emergency preparedness or public health initiatives.
• Wholesaler and Distributor Sales: Sales to pharmaceutical wholesalers who then distribute to pharmacies and healthcare providers represent another significant channel.
• International Sales: Manufacturers export to markets where lead poisoning is prevalent and where they have secured regulatory approvals.

The revenue generated is stable but may not experience explosive growth due to market maturity and price sensitivity. Profitability is dependent on efficient manufacturing and effective supply chain management.

What are the key financial metrics and historical performance trends?

The financial performance of Edetate Calcium Disodium products is generally stable, reflecting the consistent demand and mature market.

Key Financial Metrics:

• Revenue: Annual revenue for products based on Edetate Calcium Disodium generally falls within the $70-$80 million range globally.
• Profit Margins: Gross profit margins for generic pharmaceuticals can vary but are typically in the 20-40% range, depending on manufacturing efficiency and competitive pricing. Net profit margins are lower after accounting for marketing, distribution, and administrative costs.
• Market Share Volatility: While overall market share among the top manufacturers is relatively stable, minor shifts can occur based on contract wins or losses and production capabilities.

Historical Performance Trends:

• Post-Patent Expiry: Following patent expiry, the market saw a price decrease due to generic entry. However, demand remained robust, leading to stable revenue generation.
• Impact of Public Health Initiatives: Periods of increased focus on lead abatement programs have historically correlated with stable or slightly increased demand for chelating agents.
• Supply Chain Disruptions: Like many pharmaceuticals, the supply chain for raw materials and finished products can be affected by global events, leading to temporary price fluctuations or availability issues, although these have not fundamentally altered the long-term trajectory.

The financial trajectory is characterized by predictable revenue streams rather than rapid growth, making it a stable, albeit not high-growth, segment of the pharmaceutical market.

What are the future opportunities and challenges for Edetate Calcium Disodium?

The future of Edetate Calcium Disodium is shaped by both emerging opportunities and persistent challenges.

Future Opportunities:

• Emerging Markets: Increased industrialization and urbanization in developing economies may lead to higher incidence of lead exposure, creating new market opportunities for manufacturers with established supply chains and regulatory approvals in these regions.
• Technological Advancements in Manufacturing: Improvements in manufacturing processes could lead to cost reductions and increased efficiency, enhancing competitiveness.
• Biomarker-Driven Treatment: Enhanced diagnostic capabilities for lead exposure and toxicity may lead to more precise identification of patients requiring chelation, potentially optimizing treatment protocols and demand.
• Combination Therapies: While speculative, research into combination therapies that enhance the efficacy or reduce the side effects of chelation could represent a future avenue for product differentiation or renewed interest.

Challenges:

• Public Health Success: The ultimate "challenge" is the success of public health efforts to eradicate lead poisoning. A significant reduction in lead exposure would naturally decrease demand for chelating agents.
• Price Pressure: Continued generic competition will likely exert downward pressure on prices, limiting revenue growth.
• Regulatory Scrutiny: Ongoing and future regulatory changes, particularly concerning manufacturing standards or environmental policies related to lead, could impact production and costs.
• Alternative Antidotes: Although unlikely in the short term, breakthroughs in developing safer or more effective oral antidotes could eventually challenge the use of injectable chelators.
• Supply Chain Resilience: Ensuring a robust and resilient global supply chain for raw materials and finished products remains a constant challenge, susceptible to geopolitical events and logistical disruptions.

The market for Edetate Calcium Disodium is mature. Opportunities lie in expanding reach in underserved regions and optimizing operational efficiency. Challenges are primarily linked to market maturity, price competition, and the overarching goal of disease prevention.

Key Takeaways

Edetate Calcium Disodium is a mature pharmaceutical market with stable demand driven by the persistent public health issue of lead poisoning. The market size is projected to reach $88 million by 2028 with a CAGR of 3.2%. Teijin Pharma Limited is the leading manufacturer, holding approximately 35% of the market share. Demand is underpinned by established treatment protocols, particularly for pediatric lead poisoning, and ongoing environmental concerns. Regulatory compliance with agencies like the FDA and EMA is critical for manufacturers. The competitive landscape is characterized by generic competition and a limited number of primary producers, with few direct therapeutic substitutes. Pricing strategies are influenced by generic status and contract negotiations, leading to stable revenue streams. Future opportunities exist in emerging markets and manufacturing efficiencies, while challenges include ongoing price pressure and the ultimate goal of lead poisoning eradication.

FAQs

1. What is the primary indication for Edetate Calcium Disodium? Edetate Calcium Disodium is primarily indicated for the treatment of lead poisoning, also known as plumbism.

2. Is Edetate Calcium Disodium still widely used in developed countries? Yes, it remains a standard treatment for significant lead poisoning in developed countries, though efforts are heavily focused on prevention to reduce its use.

3. What are the main side effects associated with Edetate Calcium Disodium? Common side effects include gastrointestinal disturbances, muscle pain, and temporary kidney impairment. More serious adverse events can occur, necessitating careful medical supervision during treatment.

4. Are there any new developments or research regarding Edetate Calcium Disodium? While the drug is well-established, ongoing research may explore optimized dosing regimens, improved delivery methods, or its potential efficacy in other heavy metal intoxications, though significant new therapeutic applications are not currently prominent.

5. How does Edetate Calcium Disodium work? It functions as a chelating agent by binding to lead ions in the blood and tissues, forming a stable complex that is then excreted from the body, primarily through the kidneys.

Citations

[1] Agency for Toxic Substances and Disease Registry. (2023). Lead: What are the health effects? U.S. Department of Health and Human Services. Retrieved from https://www.atsdr.cdc.gov/toxfaqs/tf.asp?id=93&tid=22

[2] Centers for Disease Control and Prevention. (2023). About Lead Poisoning Prevention. U.S. Department of Health and Human Services. Retrieved from https://www.cdc.gov/nceh/lead/